Protherics PLC Notification of Major Interest in Shares London, UK; Brentwood, TN, US; 20 November 2008 - Protherics PLC ("Protherics" or the "Company"), the international biopharmaceutical company focused on critical care and cancer, announces that, on 19 November 2008, the following notification of interest in the ordinary share capital of the Company was received from Aviva plc. 1. Reason for the notification (please tick the appropriate box or boxes) A disposal voting rights X An acquisition or disposal of financial instruments which may result in the acquisition of shares already issued to which voting rights are attached An event changing the breakdown of voting rights Other (please specify): 2. Full name of person(s) subject to the Aviva plc & its notification obligation: subsidiaries 3. Full name of shareholder(s) (if different from Registered Holder: 2.): BNY Norwich Union Nominees Limited 5,959,368* Chase GA Group Nominees Limited 19,321,240* Chase Nominees Limited 879,543* CUIM Nominee Limited 4,366,418* Vidacos Nominees Limited 65,125* *denotes direct interest BNP Paribas - London 636,429 Chase Nominees Limited 3,065,451 State Street Nominees Limited 9,428,137 Vidacos Nominees Limited 1,603,080 4. Date of the transaction (and date on which the 18 November 2008threshold is crossed or reached if different): 5. Date on which issuer notified: 19 November 2008 6. Threshold(s) that is/are crossed or reached: 13% to 12% Change at Combined Interest level 7. Notified details: A: Voting rights attached to shares Class/type Situation previous of shares to the Triggering if possible transaction using the ISIN CODE Number of Number of voting Shares Rights Ordinary Shares 45,971,166 45,971,166 GB0007029209 Resulting situation after the trigger transaction Number of Number of voting & of voting rights Shares rights Direct Direct Indirect Direct Indirect 30,591,694 30,591,694 14,733,097 8.73% 4.20% B: Financial Instruments Resulting situation after the triggering transaction Type of Expiration Exercise/ Number of voting rights that % of financial date Conversion may be acquired if the voting instrument Period/ instrument is exercised/ rights Date converted. N/A Total (A+B) Number of voting rights % of voting rights 45,324,791 12.93% 8. Chain of controlled undertakings through which the voting rights and /or the financial instruments are effectively held, if applicable : The voting rights are managed and controlled by Aviva Investors Global Services Limited, with the following chain of controlled undertakings:- Aviva Investors Global Services Limited: - Aviva plc (Parent Company) - Aviva Group Holdings Limited (wholly owned subsidiary of Aviva plc) - Aviva Investors Holdings Limited (wholly owned subsidiary of Aviva Group Holdings Limited) - Aviva Investors Global Services Limited (wholly owned subsidiary of Aviva Investors Holdings Limited) Proxy Voting: 9. Name of the proxy holder: See Section 3 10. Number of voting rights proxy holder will cease to hold: 11. Date on which proxy holder will cease to hold voting rights: 12. Additional Figures are based on a revised total number of information: voting rights of 350,427,481 / Ends / For further information please contact: Protherics Nick Staples, Director of Corporate Affairs +44 (0) 7919 480510 Julie Vickers, Company Secretary +44 (0)1928 518010 Financial Dynamics - press enquiries London: Ben Atwell, Lara Mott +44 (0) 20 7831 3113 New York: John Capodanno +1 212 850 5600 Or visit www.protherics.com This information is provided by RNS The company news service from the London Stock Exchange END
Contact Information: Contacts: RNS Customer Services 0044-207797-4400 http://www.rns.com